Physician profile
Sixto Perez
NPI 1649240110
$34,752.51
in general payments reported to CMS, 2019-2025
49 companies · $3,653 in 2025
The $3,653 reported for 2025 was more than what 77% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,044 · 2020: $12K · 2021: $2,901 · 2022: $2,451 · 2023: $2,644 · 2024: $3,235 · 2025: $3,653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,432 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,432.40 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $6,730.60 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $4,751.40 | 2019-2024 | Darzalex, Imbruvica, Tecvayli |
| E.R. Squibb & Sons, L.L.C. | $4,044.86 | 2019-2025 | Opdivo, Reblozyl, Opdualag |
| Merck Sharp & Dohme LLC | $3,839.93 | 2019-2024 | Keytruda |
| Astrazeneca Pharmaceuticals LP | $1,963.95 | 2019-2024 | Imfinzi, Lynparza, Enhertu |
| Abbvie INC. | $1,797.79 | 2019-2025 | |
| Genentech USA, INC. | $1,347.87 | 2019-2025 | Polivy, Tecentriq, Lunsumio |
| Eli Lilly Export S.A. Puerto Rico Branch | $1,276.77 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Novartis Pharmaceuticals Corporation | $923.57 | 2019-2025 | |
| Amgen INC. | $907.45 | 2019-2023 | Xgeva, Lumakras, Kyprolis |
| Genzyme Corporation | $616.68 | 2019-2025 | |
| Eisai INC. | $524.71 | 2019-2025 | |
| Taiho Oncology, INC. | $523.86 | 2019-2025 | |
| Incyte Corporation | $484.58 | 2019-2025 | Monjuvi, Pemazyre, Jakafi |
| Bayer Puerto Rico INC. | $454.14 | 2023-2025 | Nubeqa, Stivarga, Vitrakvi |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sixto Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.